Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT03588286
Registration number
NCT03588286
Ethics application status
Date submitted
4/07/2018
Date registered
17/07/2018
Date last updated
7/05/2024
Titles & IDs
Public title
Programmed Ventricular Stimulation to Risk Stratify for Early Cardioverter-Defibrillator (ICD) Implantation to Prevent Tachyarrhythmias Following Acute Myocardial Infarction (PROTECT-ICD)
Query!
Scientific title
Programmed Ventricular Stimulation to Risk Stratify for Early Cardioverter-Defibrillator (ICD) Implantation to Prevent Tachyarrhythmias Following Acute Myocardial Infarction (PROTECT-ICD)
Query!
Secondary ID [1]
0
0
ACTRN12614000042640
Query!
Secondary ID [2]
0
0
PROTECT-ICD, Version 5
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
PROTECT-ICD
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Sudden Cardiac Death
0
0
Query!
Condition category
Condition code
Cardiovascular
0
0
0
0
Query!
Coronary heart disease
Query!
Cardiovascular
0
0
0
0
Query!
Other cardiovascular diseases
Query!
Cardiovascular
0
0
0
0
Query!
Diseases of the vasculature and circulation including the lymphatic system
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Surgery - Electrophysiology study (EPS)
Other interventions - Standard Care
Treatment: Surgery - Cardiac Magnetic Resonance (CMR)
Experimental: Intervention Arm (Early EPS) - The intervention group all undergo electrophysiologic study early after myocardial infarction (within 40 days of MI).
If the study is positive (inducible monomorphic ventricular tachycardia of cycle length greater than or equal to 200ms) participants have an ICD implanted. Participants with a negative study (no inducible arrhythmia or induced ventricular fibrillation/ ventricular flutter cycle length \<200ms) are discharged without an ICD.
A proportion of trial patients from both the intervention and control arms at \>48 hours following revascularisation for STEMI will undergo CMR to enable correlation with (1) inducible VT at EPS and (2) SCD and non-fatal arrhythmia on follow up. CMR will simultaneously assess left ventricular function, ventricular strain, myocardial infarction size, and peri-infarction injury.
Active comparator: Control Arm (Standard Care) - The control group receive ongoing standard care according to the practise of their institution. This includes discharge from hospital as per their treating physician and follow up as usual in the community. Participants in this group would be eligible to receive an ICD according to the standard practise of their cardiologist (guideline recommendations are after 40 days following myocardial infarction or 90 days following revascularisation only in patients with left ventricular ejection fraction less than or equal to 30% or less than or equal to 35% in the presence of heart failure).
A proportion of trial patients from both the intervention and control arms at \>48 hours following revascularisation for STEMI will undergo CMR to enable correlation with (1) inducible VT at EPS and (2) SCD and non-fatal arrhythmia on follow up. CMR will simultaneously assess left ventricular function, ventricular strain, myocardial infarction size, and peri-infarction injury.
Treatment: Surgery: Electrophysiology study (EPS)
EPS will be performed in all patients in the intervention arm with programmed ventricular stimulation with a drive train of 8 beats at 400 ms with up to 4 extrastimuli and stimulation from the right ventricular apex with current delivered at twice pacing threshold. The end point for stimulation will be sustained monomorphic ventricular tachycardia (VT) lasting \> 10 seconds. If sustained monomorphic VT with cycle length (CL) =200ms is induced by =4 extra stimuli the EPS result will be considered positive for inducible VT.30 Ventricular fibrillation or flutter with CL\<200ms will be considered a negative result. The Programmed Ventricular Stimulation (PVS) induction will be repeated a second time if the initial induction was negative for VT.
Other interventions: Standard Care
The control group receive ongoing standard care according to the practise of their institution. This includes discharge from hospital as per their treating physician and follow up as usual in the community. Participants in this group would be eligible to receive an ICD according to the standard practise of their cardiologist (guideline recommendations are after 40 days following myocardial infarction or 90 days following revascularisation only in patients with left ventricular ejection fraction less than or equal to 30% or less than or equal to 35% in the presence of heart failure).
Treatment: Surgery: Cardiac Magnetic Resonance (CMR)
CMR will be performed on either a 1.5-T or 3-T scanner. Gadolinium contrast (Gd-BOPTA, MultihanceTM) will be administered for quantification myocardial perfusion imaging with subsequent late gadolinium enhanced imaging after a total dose of 0.1mmol/kg. Exclusion criteria specific for CMR will include pregnancy, renal insufficiency defined as glomerular filtration rate (GFR) \<30 mL/min, contraindication to MRI (including non-MRI compatible pacemaker/ICD or metal implants, non-MR safe prosthetic heart valves), claustrophobia which cannot be controlled via standard methods (benzodiazepines and/or sedative antihistamine administration) and prior allergic reaction to gadolinium-based contrast agent.
Query!
Intervention code [1]
0
0
Treatment: Surgery
Query!
Intervention code [2]
0
0
Other interventions
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Sudden cardiac death
Query!
Assessment method [1]
0
0
Cause of death will be determined based on information obtained from witnesses, family members, death certificates, hospital records and autopsy or coroner reports. Sudden cardiac death will be explicitly defined as death that occurs "suddenly and unexpectedly" in a patient in otherwise stable condition and includes witnessed instantaneous deaths (with or without documentation of arrhythmia), unwitnessed deaths if the patient had been seen within 24 hours before death (in the absence of another clear cause of death), deaths caused by incessant ventricular tachyarrhythmia, deaths considered a sequel of cardiac arrest and deaths resulting from pro-arrhythmia of anti-arrhythmic drugs.31 The remainder of deaths will be classified as either non-sudden cardiovascular death, or non-cardiovascular death. Operative deaths associated with the implantation of an ICD will be counted as non-sudden cardiovascular death.
Query!
Timepoint [1]
0
0
2 years after randomisation
Query!
Primary outcome [2]
0
0
Non-fatal arrhythmia
Query!
Assessment method [2]
0
0
Non-fatal arrhythmia includes resuscitated cardiac arrest, sustained ventricular tachycardia (VT) and ventricular fibrillation (VF) in participants without an ICD. Resuscitated cardiac arrest is defined as a sudden circulatory arrest requiring cardiopulmonary resuscitation (CPR) (with or without documented arrhythmia) from which the patient regains consciousness. VT and VF are defined as ECG or telemetry-documented ventricular tachycardia or ventricular fibrillation. Only sustained ventricular tachycardia will be included (greater than 30 seconds of VT) or if the VT required emergency treatment with anti-arrhythmic medications or electrical cardioversion.
Query!
Timepoint [2]
0
0
2 years after randomisation
Query!
Secondary outcome [1]
0
0
All-cause mortality
Query!
Assessment method [1]
0
0
All deaths.
Query!
Timepoint [1]
0
0
2 years after randomisation
Query!
Secondary outcome [2]
0
0
Non-sudden cardiovascular death
Query!
Assessment method [2]
0
0
Non-sudden cardiovascular deaths will be classified as death due to myocardial infarction, heart failure or another cardiovascular cause including cerebrovascular or peripheral vascular causes.
Query!
Timepoint [2]
0
0
2 years after randomisation
Query!
Secondary outcome [3]
0
0
Non-fatal repeat MI
Query!
Assessment method [3]
0
0
Non-fatal repeat MI requires the presence of two of the following three: symptoms of myocardial ischaemia, a characteristic rise and fall in cardiac markers and a typical ECG pattern involving the development of Q waves or persistent T wave changes.
Query!
Timepoint [3]
0
0
2 years after randomisation
Query!
Secondary outcome [4]
0
0
Heart failure
Query!
Assessment method [4]
0
0
Heart failure is defined as symptoms or signs consistent with congestive heart failure with use of intravenous decongestive therapy greater than 2 hours (IV diuretics, IV nesiritide, IV inotropes) in a patient not requiring hospital admission, or, augmented heart failure regimen with oral or intravenous medications in patients requiring hospital admission.
Query!
Timepoint [4]
0
0
2 years after randomisation
Query!
Secondary outcome [5]
0
0
Inappropriate ICD denial
Query!
Assessment method [5]
0
0
Inappropriate ICD denial will be defined as patients who did not receive an ICD based on their intervention allocation, who went on to have documented non-fatal arrhythmia or sudden cardiac death.
Query!
Timepoint [5]
0
0
2 years after randomisation
Query!
Secondary outcome [6]
0
0
Appropriate ICD activations (in patients with ICD)
Query!
Assessment method [6]
0
0
Appropriate ICD activation will be defined as ventricular tachyarrhythmia due to VT which meets the treatment criteria defined above or VF.
Query!
Timepoint [6]
0
0
2 years after randomisation
Query!
Secondary outcome [7]
0
0
Inappropriate ICD activations (in patients with ICD)
Query!
Assessment method [7]
0
0
Inappropriate ICD activations will include supra-ventricular tachycardia, atrial fibrillation/flutter, T wave over-sensing, sinus tachycardia and noise from lead complications or extraneous noise.
Query!
Timepoint [7]
0
0
2 years after randomisation
Query!
Secondary outcome [8]
0
0
Complications or re-hospitalisation associated with ICD implantation (in patients with ICD)
Query!
Assessment method [8]
0
0
Complications or re-hospitalisation associated with ICD implantation (in patients with ICD)
Query!
Timepoint [8]
0
0
2 years after randomisation
Query!
Eligibility
Key inclusion criteria
* 2-40 days (inclusive) following a myocardial infarct
* Impaired left ventricular systolic function (LVEF=40% or at least moderately impaired)
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
85
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Age <18 or >85;
2. Pregnancy;
3. Nursing home resident dependent on one or more activities of daily living;
4. Significant non-cardiac co-morbidity with high likelihood of death within 1 year (this would include any metastatic malignancy, or other terminal disease);
5. Significant psychiatric illnesses that may be aggravated by device implantation or that may preclude regular follow up;
6. Intravenous drug abuse (ongoing);
7. Unresolved infection associated with risk for hematogenous seeding;
8. Pre-existing implantable cardioverter-defibrillator (ICD);
9. Secondary prevention indication for an ICD (i.e. sustained ventricular arrhythmias occurring more than 48 hours after qualifying myocardial infarction (patients with ventricular arrhythmias occurring =48 hours of myocardial infarction, or with non-sustained ventricular tachycardia at any time, are not excluded));
10. On the heart transplant list;
11. Recurrent unstable angina despite revascularisation (defined as ongoing chest pain or ischemic symptoms at rest or with minimal exertion despite adequate treatment with anti-anginal medications);**
12. Congestive heart failure New York Heart Association class IV, defined as shortness of breath at rest, which is refractory to medical treatment (not responding to treatment)** **NOTE: patients who meet exclusion based on (11) or (12) can be reviewed again in 2-3 days and if symptoms have resolved or treatment performed can be re-considered for inclusion.
Query!
Study design
Purpose of the study
Prevention
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
NA
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
27/02/2014
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
6/12/2029
Query!
Actual
Query!
Sample size
Target
1058
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
ACT,NSW,QLD,SA,VIC
Query!
Recruitment hospital [1]
0
0
Canberra Hospital - Garran
Query!
Recruitment hospital [2]
0
0
Nepean Hospital - Kingswood
Query!
Recruitment hospital [3]
0
0
John Hunter Hospital - New Lambton Heights
Query!
Recruitment hospital [4]
0
0
Prince of Wales Hospital - Randwick
Query!
Recruitment hospital [5]
0
0
Royal North Shore Hospital - Saint Leonards
Query!
Recruitment hospital [6]
0
0
Westmead Hospital - Westmead
Query!
Recruitment hospital [7]
0
0
Wollongong Hospital - Wollongong
Query!
Recruitment hospital [8]
0
0
Sunshine Coast University Hospital - Birtinya
Query!
Recruitment hospital [9]
0
0
Carins Hospital - Cairns
Query!
Recruitment hospital [10]
0
0
The Prince Charles Hospital - Chermside
Query!
Recruitment hospital [11]
0
0
The Townsville Hospital - Douglas
Query!
Recruitment hospital [12]
0
0
Royal Brisbane and Women's Hospital - Herston
Query!
Recruitment hospital [13]
0
0
Gold Coast University Hospital - Southport
Query!
Recruitment hospital [14]
0
0
Princess Alexandra Hospital - Woolloongabba
Query!
Recruitment hospital [15]
0
0
Lyell McEwin Hospital - Elizabeth Vale
Query!
Recruitment hospital [16]
0
0
MonashHeart - Clayton
Query!
Recruitment hospital [17]
0
0
Northern Hospital - Epping
Query!
Recruitment hospital [18]
0
0
Austin Hospital - Melbourne
Query!
Recruitment hospital [19]
0
0
Western Health, Sunshine and Footscray Hospitals - Melbourne
Query!
Recruitment postcode(s) [1]
0
0
2605 - Garran
Query!
Recruitment postcode(s) [2]
0
0
2747 - Kingswood
Query!
Recruitment postcode(s) [3]
0
0
2305 - New Lambton Heights
Query!
Recruitment postcode(s) [4]
0
0
2031 - Randwick
Query!
Recruitment postcode(s) [5]
0
0
2065 - Saint Leonards
Query!
Recruitment postcode(s) [6]
0
0
2145 - Westmead
Query!
Recruitment postcode(s) [7]
0
0
2500 - Wollongong
Query!
Recruitment postcode(s) [8]
0
0
4575 - Birtinya
Query!
Recruitment postcode(s) [9]
0
0
4870 - Cairns
Query!
Recruitment postcode(s) [10]
0
0
4032 - Chermside
Query!
Recruitment postcode(s) [11]
0
0
4814 - Douglas
Query!
Recruitment postcode(s) [12]
0
0
4029 - Herston
Query!
Recruitment postcode(s) [13]
0
0
4215 - Southport
Query!
Recruitment postcode(s) [14]
0
0
4102 - Woolloongabba
Query!
Recruitment postcode(s) [15]
0
0
5112 - Elizabeth Vale
Query!
Recruitment postcode(s) [16]
0
0
3168 - Clayton
Query!
Recruitment postcode(s) [17]
0
0
3076 - Epping
Query!
Recruitment postcode(s) [18]
0
0
3084 - Melbourne
Query!
Recruitment postcode(s) [19]
0
0
- Melbourne
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Massachusetts
Query!
Country [2]
0
0
Czechia
Query!
State/province [2]
0
0
Prague
Query!
Country [3]
0
0
Germany
Query!
State/province [3]
0
0
Bad Neustadt An Der Saale
Query!
Country [4]
0
0
Germany
Query!
State/province [4]
0
0
Brandenburg
Query!
Country [5]
0
0
Germany
Query!
State/province [5]
0
0
Göttingen
Query!
Country [6]
0
0
Germany
Query!
State/province [6]
0
0
Leipzig
Query!
Country [7]
0
0
Greece
Query!
State/province [7]
0
0
Athens
Query!
Country [8]
0
0
Greece
Query!
State/province [8]
0
0
Iraklio
Query!
Country [9]
0
0
Hungary
Query!
State/province [9]
0
0
Budapest
Query!
Country [10]
0
0
Hungary
Query!
State/province [10]
0
0
Debrecen
Query!
Country [11]
0
0
Hungary
Query!
State/province [11]
0
0
Pécs
Query!
Country [12]
0
0
Israel
Query!
State/province [12]
0
0
Jerusalem
Query!
Country [13]
0
0
Latvia
Query!
State/province [13]
0
0
Riga
Query!
Country [14]
0
0
Malaysia
Query!
State/province [14]
0
0
Kuala Lumpur
Query!
Country [15]
0
0
New Zealand
Query!
State/province [15]
0
0
Auckland
Query!
Country [16]
0
0
New Zealand
Query!
State/province [16]
0
0
Hamilton
Query!
Country [17]
0
0
New Zealand
Query!
State/province [17]
0
0
Christchurch
Query!
Country [18]
0
0
New Zealand
Query!
State/province [18]
0
0
Wellington
Query!
Country [19]
0
0
Poland
Query!
State/province [19]
0
0
Warszawa
Query!
Country [20]
0
0
Poland
Query!
State/province [20]
0
0
Lódz
Query!
Country [21]
0
0
Russian Federation
Query!
State/province [21]
0
0
Saint Petersburg
Query!
Country [22]
0
0
Russian Federation
Query!
State/province [22]
0
0
Samara
Query!
Country [23]
0
0
Singapore
Query!
State/province [23]
0
0
Singapore
Query!
Country [24]
0
0
Slovakia
Query!
State/province [24]
0
0
Bratislava
Query!
Country [25]
0
0
Switzerland
Query!
State/province [25]
0
0
Basel
Query!
Country [26]
0
0
Switzerland
Query!
State/province [26]
0
0
Bern
Query!
Country [27]
0
0
Switzerland
Query!
State/province [27]
0
0
Lausanne
Query!
Funding & Sponsors
Primary sponsor type
Other
Query!
Name
Western Sydney Local Health District
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The PROTECT-ICD trial is a physician-led, multi-centre randomised controlled trial targeting prevention of sudden cardiac death in patients who have poor cardiac function following a myocardial infarct (MI). The trial aims to assess the role of electrophysiology study (EPS) in guiding implantable cardioverter-defibrillator (ICD) implantation, in patients early following MI (first 40 days). The secondary aim is to assess the utility of cardiac MRI (CMR) in analysing cardiac function and viability as well as predicting inducible and spontaneous ventricular tachyarrhythmia when performed early post MI. Following a MI patients are at high risk of sudden cardiac death (SCD). The risk is highest in the first 40 days; however, current guidelines exclude patients from receiving an ICD during this time. This limitation is based largely on a single study, The Defibrillator in Acute Myocardial Infarction Trial (DINAMIT), which failed to demonstrate a benefit of early ICD implantation. However, this study was underpowered and used non-invasive tests to identify patients at high risk. EPS identifies patients with the substrate for re-entrant tachyarrhythmia, and has been found in multiple studies to predict patients at risk of SCD. Contrast-enhanced CMR is a non-invasive test without radiation exposure which can be used to assess left ventricular function. In addition, it provides information on myocardial viability, scar size and tissue heterogeneity. It has an emerging role as a predictor of mortality and spontaneous ventricular arrhythmia in patients with a previous MI. A total of 1,058 patients who are at high risk of SCD based on poor cardiac function (left ventricular ejection fraction (LVEF) =40%) following a ST-elevation or non-STE myocardial infarct will be enrolled in the trial. Patients will be randomised 1:1 to either the intervention or control arm. In the intervention arm all patients undergo early EPS. Patients with a positive study (inducible ventricular tachycardia cycle length =200ms) receive an ICD, while patients with a negative study (inducible ventricular fibrillation or no inducible VT) are discharged without an ICD, regardless of the LVEF. In the control arm patients are treated according to standard local practice. This involves early discharge and repeat assessment of cardiac function after 40 days or after 90 days following revascularisation (PCI or CABG). ICD implantation after 40 days according to current guidelines (LVEF=30%, or =35% with New York Heart Association (NYHA) class II/III symptoms) could be considered, if part of local standard practice, however the ICD is not funded by the trial. A proportion of trial patients from both the intervention and control arms at \>48 hours following MI will undergo CMR to enable correlation with (1) inducible VT at EPS and (2) SCD and non-fatal arrhythmia on follow up. It will be used to simultaneously assess left ventricular function, ventricular strain, myocardial infarction size, and peri-infarction injury. The size of the infarct core, infarct gray zone (as a measure of tissue heterogeneity) and total infarct size will be quantified for each patient. All patients will be followed for 2 years with a combined primary endpoint of non-fatal arrhythmia and SCD. Non-fatal arrhythmia includes resuscitated cardiac arrest, sustained ventricular tachycardia (VT) and ventricular fibrillation (VF) in participants without an ICD. Secondary endpoints will include all-cause mortality, non-sudden cardiovascular death, non-fatal repeat MI, heart failure and inappropriate ICD denial. Secondary endpoints for CMR correlation will include (1) the presence or absence of inducible VT at EP study, and (2) combined endpoint of appropriate ICD activation or SCD at follow up. It is anticipated that the intervention arm will reduce the primary endpoint as a result of prevention of a) early sudden cardiac deaths/cardiac arrest, and b) sudden cardiac death/cardiac arrest in patients with a LVEF of 31-40%. It is expected that the 2-year primary endpoint rate will be reduced from 6.7% in the control arm to 2.8% in the intervention arm with a relative risk reduction (RRR) of 68%. A two-group chi-squared test with a 0.05 two-sided significance level will have 80% power to detect the difference between a Group 1 proportion of 0.028 experiencing the primary endpoint and a Group 2 proportion of 0.067 experiencing the primary endpoint when the sample size in each group is 470. Assuming 1% crossover and 10% loss to follow up the required sample size is 1,058 (n=529 patients per arm). To test the hypothesis that tissue heterogeneity at CMR predicts both inducible and spontaneous ventricular tachyarrhythmias will require a sample size of 400 patients to undergo CMR. It is anticipated that the use of EPS will select a group of patients who will benefit from an ICD soon after a MI. This has the potential to change clinical guidelines and save a large number of lives.
Query!
Trial website
https://clinicaltrials.gov/study/NCT03588286
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Study Principal Investigator Study Principal Investigator
Query!
Address
0
0
Western Sydney Local Health District
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Pramesh Kovoor
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
+61 2 8890 6030
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT03588286
Download to PDF